{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-016110","form_type":"8-K","ticker":"ABPO","cik":"0001893219","company_name":"Abpro Holdings, Inc.","filed_at":"2025-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.501785+00:00","generated_at":"2026-05-26T07:17:45.325707+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Abpro provides pipeline update; Celltrion partnership for ABP-102 fully funded with up to $1.75B milestones","bullets":["Celltrion funds all development of ABP-102 (HER2/CD3 T-cell engager) for breast/gastric cancer; Abpro retains 50% profit share.","ABP-201 (VEGF/ANG2) for Wet AMD/DME: IND filing expected Q1 2026, Phase 1 start same year.","ABP-102 IND filing targeted for 2H 2025; Phase 1 initiation in 1H 2026.","Additional pipeline: ABP-150 (Claudin18.2/CD3) and ABP-110 (GPC3/CD3) IND filings in 2026, Phase 1 in 2027.","No financial results; presentation highlights platform, preclinical data, and upcoming milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-016110","json":"https://secwatch.observer/filing/0001213900-25-016110.json","markdown":"https://secwatch.observer/filing/0001213900-25-016110.md","text":"https://secwatch.observer/filing/0001213900-25-016110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1893219/000121390025016110/0001213900-25-016110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1893219/000121390025016110/ea0231728-8k_abpro.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T07:17:45.325707+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}